Tyrosinase-related protein 2 (Trp2) (TRP2)

The target 'CD8+ T cells recognizing H-2Kb–Trp2 complex' describes a specific immune interaction rather than a single molecule; however, it primarily refers to the therapeutic targeting of Tyrosinase-related protein 2 (Trp2). Trp2, also known as dopachrome tautomerase (DCT), is a 519-amino acid enzyme essential for melanin biosynthesis within melanocytes (UniProt P20260). In murine melanoma models such as B16, the Trp2-derived peptide fragment SVYDFFVWL (residues 180-188) is processed and presented on the cell surface by the MHC class I molecule H-2Kb (Bloom et al., 1997, J. Exp. Med.). This H-2Kb–Trp2 complex is a major melanoma-associated antigen (MAA) and serves as a primary target for CD8+ cytotoxic T lymphocytes (CTLs), which recognize the complex via their T-cell receptors (TCRs) to initiate tumor cell lysis. Therapeutic strategies targeting this pathway include peptide-based vaccines, DNA vaccines (e.g., SCIB1), and adoptive transfer of TCR-engineered T cells designed to expand the population of Trp2-specific CD8+ T cells. A significant challenge and safety concern associated with targeting Trp2 is the potential for autoimmune vitiligo, as the protein is also expressed in healthy melanocytes (Overwijk et al., 1999, PNAS).

Other names

Dopachrome tautomeraseDCTTRP-2L-dopachrome Delta-isomeraseTyrosinase-related protein 2

Induction of antigen-specific cytotoxic T lymphocyte (CTL) response via T-cell receptor (TCR) recognition of the H-2Kb–Trp2 peptide complex.